Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis

Eosinophilic esophagitis (EoE) is an allergen-mediated inflammatory disease with no approved treatment in the United States. Dupilumab, a VelocImmune-derived human monoclonal antibody against the interleukin 4 (IL4) receptor, inhibits IL4 and IL13 signaling. Dupilumab is effective in treatment of allergic, atopic, and type 2 diseases, so we assessed its efficacy and safety in patients with EoE.

Source: Gastroenterology - October 4, 2019 Category: Gastroenterology Authors: Ikuo Hirano, Evan S. Dellon, Jennifer D. Hamilton, Margaret H. Collins, Kathryn Peterson, Mirna Chehade, Alain M. Schoepfer, Ekaterina Safroneeva, Marc E. Rothenberg, Gary W. Falk, Yehudith Assouline-Dayan, Qiong Zhao, Zhen Chen, Brian N. Swanson, Gianluc Source Type: research